• TEAM

    • STEPHEN BERGE, Ph.D.
    • TOM BURKE
    • PHILIP CHAIKIN, PharmD., MD, F.C.P.
    • DENIS DARKO, MD, F.A.C.P.
    • STEVE ELROD, Ph.D., DABT
    • MARK ROBBINS, Ph.D., J.D.
    • BERT SPILKER, PhD, MD, FCP, FFPM
    • TOM WILLARD

  • SERVICES

    • FUNDRAISING AND INVESTMENT
    • BUSINESS PLAN DEVELOPMENT
    • DRUG COMMERCIALIZATION
    • DRUG DEVELOPMENT
    • LITIGATION SUPPORT SERVICES
    • REGULATORY SERVICES

  • CONTACT

  • NEWS

  • More

    Use tab to navigate through the menu items.

    A lecture at the University of MN College of Pharmacy, presented by Mark S. Robbins on April 11, 201

    The Impact of Hatch Waxman and Antitrust Liability on Incremental Innovation_DOWNLOAD
    Featured Articles

    PATENT PHARMA DAMAGES AFTER AN AT-RISK LAUNCH: A REAL WORLD APPROACH

    A lecture at the University of MN College of Pharmacy, presented by Mark S. Robbins on April 11, 201

    The Bial 10-2474 Phase 1 Study— A Drug Development Perspective and Recommendations for Future First-

    Life Sciences: The isolated human umbilical vein as a bioassay for kinin-generating proteases: An in

    Recent Articles

    PATENT PHARMA DAMAGES AFTER AN AT-RISK LAUNCH: A REAL WORLD APPROACH

    A lecture at the University of MN College of Pharmacy, presented by Mark S. Robbins on April 11, 201

    The Bial 10-2474 Phase 1 Study— A Drug Development Perspective and Recommendations for Future First-

    Life Sciences: The isolated human umbilical vein as a bioassay for kinin-generating proteases: An in

    Pharmacological effects of recombinant human tissue kallikrein on bradykinin B2 receptors

    Archive
    • July 2018 (1) 1 post
    • April 2018 (1) 1 post
    • January 2018 (3) 3 posts
    Search By Tags
    No tags yet.
    Follow Us
    • Facebook Basic Square
    • Twitter Basic Square
    • Google+ Basic Square

    © 2018 Kodiak Strategic Consulting. All rights reserved.